ES cell cytoplasm or ooplasm transfer to rejuventate recipient cells
US9580683B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jun 11, 2014 |
| Grant date | Feb 28, 2017 |
| Priority date | — |
| Expiry date | Jun 11, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2517/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.